The cumulative lifetime risk of ovarian cancer is estimated to be 6–10% in proven or probable MSH2 and MLH1 mutation carriers, with an average age of onset of 51 years in families associated with MLH1 mutations and 45 years in families associated with MSH2 mutations [24–26]. This evidence concerns the gene MLH1 and ovarian cancer.